Welcome to our dedicated page for AC Immune SA news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune SA stock.
AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, committed to pioneering precision medicine for neurodegenerative diseases. The company specializes in designing, discovering, and developing innovative therapeutic and diagnostic products aimed at preventing and modifying diseases caused by misfolded proteins. Utilizing its two proprietary technology platforms, SupraAntigen® and Morphomer®, AC Immune develops a broad spectrum of antibodies, small molecules, and vaccines targeting conditions such as Alzheimer’s disease (AD), Parkinson’s disease, and NeuroOrphan indications.
With a robust pipeline consisting of sixteen therapeutic and diagnostic programs, AC Immune currently has six product candidates in clinical trials, including five in Phase 2 and one in Phase 3. The most advanced candidate, Crenezumab, is a humanized anti-amyloid-β monoclonal antibody in Phase 3 trials aimed at treating Alzheimer’s disease. Other notable candidates include ACI-24.060, a promising anti-Abeta active immunotherapy for AD and Down syndrome, which has received FDA Fast Track Designation, and ACI-35.030, an anti-pTau active immunotherapy in Phase 2b trials for preclinical AD conducted by Janssen Pharmaceuticals.
Beyond its rich pipeline, AC Immune is known for its strategic partnerships with leading global pharmaceutical companies such as Genentech (a Roche Group member), Eli Lilly and Company, and Takeda. These collaborations have resulted in significant non-dilutive funding and milestone payments totaling over $4.5 billion.
AC Immune recently secured an exclusive option and license agreement with Takeda for its ACI-24.060 product, potentially worth $2.1 billion, and completed a $50 million equity financing to support its operations into 2026. The company's focused efforts on precision prevention are reinforced by its ongoing Phase 2 trials and collaborations aimed at leveraging advanced diagnostic techniques like PET imaging and novel therapeutic approaches for early and effective intervention in neurodegenerative diseases.
AC Immune SA (NASDAQ: ACIU) has received approximately USD 1.5 million in grants from The Michael J. Fox Foundation for Parkinson’s Research. This funding will support the development of innovative small molecules aimed at inhibiting alpha-synuclein (a-syn) aggregation and NLRP3 inflammasome activation in Parkinson’s disease. The grants enhance AC Immune's research capabilities and expand its portfolio, including an anti-a-syn vaccine and a novel imaging tracer, showcasing its commitment to precision medicine in treating neurodegenerative diseases.
AC Immune SA (NASDAQ: ACIU) presented promising interim Phase 1b/2a trial results for ACI-35.030, a vaccine targeting pathological tau in Alzheimer's disease, at the 14th CTAD conference. The data shows significant antibody induction against pTau and its aggregated forms, indicating strong immunogenicity. Safety data revealed no clinically relevant concerns. The trial has expanded to 24 participants to support late-stage development. The results suggest potential for early intervention in Alzheimer's treatment, with further data expected from the ongoing study.
AC Immune announced positive topline results from its Phase 2 Lauriet study of semorinemab, an anti-Tau monoclonal antibody for mild-to-moderate Alzheimer’s disease (AD). The study achieved a 43.6% reduction in cognitive decline at week 49 as measured by the ADAS-Cog11 scale, confirming the treatment's efficacy across various subgroups. However, it did not meet the second co-primary endpoint related to daily living activities. Safety results were positive, indicating semorinemab had an acceptable safety profile with no unexpected adverse events. The ongoing open-label study aims to further assess long-term effects.
AC Immune SA (NASDAQ: ACIU) reported progress in its clinical trials and financial results for Q3 2021, achieving its first positive cognitive results for a Tau-targeting monoclonal antibody in Alzheimer’s disease. The Phase 2 Lauriet trial showed a statistically significant 43.6% reduction in cognitive decline. The company enhanced its portfolio through the acquisition of an alpha-synuclein vaccine candidate. Financially, AC Immune holds CHF 188.6 million in cash, sufficient to fund operations through Q1 2024, despite a net loss of CHF 15.9 million for the quarter.
AC Immune SA (NASDAQ: ACIU), a biopharmaceutical company based in Switzerland, is extending its research partnership with the University of Pennsylvania focused on TDP-43 proteinopathies. The collaboration aims to explore the mechanisms of TDP-43 misfolding and cell-to-cell transmission, which are important in neurodegenerative diseases like ALS and Alzheimer's. The initial research demonstrated distinct TDP-43 species affecting disease progression. AC Immune is also advancing its lead anti-TDP-43 antibody and developing a PET tracer for diagnostics.
AC Immune SA (NASDAQ: ACIU) announced the presentation of new data on its Alzheimer’s disease candidates at the upcoming Clinical Trials on Alzheimer’s Disease (C-TAD) Conference in Boston from November 9-12, 2021. Highlights include:
- Semorinemab: Phase 2 trial results presented on November 10.
- ACI-35.030: Interim Phase 1b/2a data on safety presented on November 12.
- ACI-24: Phase 2 study results from November 9-12.
This continues AC Immune's focus on neurodegenerative diseases with a pipeline of clinical candidates.
AC Immune (NASDAQ: ACIU) has appointed Dr. Monica Shaw and Prof. Monika Bütler to its Board of Directors following an extraordinary general meeting (EGM). They replace Mr. Martin Velasco and Dr. Peter Bollmann. Dr. Shaw brings extensive drug development experience, while Prof. Bütler contributes expertise in economics and public policy. Both express enthusiasm about advancing AC Immune's mission in precision medicine for neurodegenerative diseases like Alzheimer’s. The company has a strong pipeline and partnerships that may enhance shareholder value.
AC Immune SA (NASDAQ: ACIU) announced participation in the Jefferies London Healthcare Conference on November 18-19, 2021. CEO Prof. Andrea Pfeifer will lead a fireside chat discussing the company’s corporate strategy, focusing on precision medicine and ongoing clinical trials, including the Lauriet Phase 2 trial of semorinemab for Alzheimer’s disease. The fireside chat will be available on-demand during the conference and later on AC Immune’s website. The company continues to advance its pipeline aimed at treating neurodegenerative diseases.
AC Immune SA (NASDAQ: ACIU) announced that its Co-Founder and CEO, Andrea Pfeifer, received the SEF.WomenAward for CEO of the Year at the Swiss Economic Forum on September 2, 2021. The award acknowledges the exemplary entrepreneurial achievements of women. Pfeifer emphasized the importance of recognizing talent in the field of neurodegenerative diseases, stating that their work, alongside pharmaceutical partners, aims to advance a diversified pipeline targeting these critical health challenges. AC Immune focuses on personalized medicine for conditions like Alzheimer’s and Parkinson’s.
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical firm, has announced its participation in several upcoming virtual investor conferences. Key events include the Citi’s 16th Annual BioPharma Virtual Conference on September 8 and Morgan Stanley’s 19th Annual Global Healthcare Conference on September 10. During these conferences, CEO Prof. Andrea Pfeifer will present the company’s corporate strategy and discuss its clinical-stage vaccine programs targeting neurodegenerative diseases. A webcast of the presentations will be available on AC Immune’s website.
FAQ
What is the current stock price of AC Immune SA (ACIU)?
What is the market cap of AC Immune SA (ACIU)?
What is AC Immune's primary focus?
What are AC Immune's most advanced product candidates?
What technology platforms does AC Immune use?
Who are AC Immune's strategic partners?
What is the significance of the recent agreement with Takeda?
How is AC Immune funded?
What is AC Immune’s financial outlook?
What ongoing clinical trials is AC Immune conducting?
What recent milestones has AC Immune achieved?
How does AC Immune contribute to the field of neurodegenerative disease research?
